Episode 845
TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin
December 25, 202147m 55s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
Hosts: Daniel Griffin and Vincent RacanielloSubscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- FDA EUA for Paxlovid (pdf)
- Children and COVID-19 (pdf)
- Evaluation of test to stay in school, IL (MMWR)
- Evaluation of test to stay in school, LA (MMWR)
- Update on mRNA vaccine in under 5 yo (Pfizer)
- CDC endorses preference for mRNA vaccines (CDC)
- Natural immunity and protection against delta (Clin Inf Dis)
- Cross-neutralization post-vaccination infection (JAMA)
- Variants and therapeutics (NIH)
- Quarantine and isolation (CDC)
- Molnupiravir in non-hospitalized patients (NEJM)
- Convalescent serum for outpatients (medRxiv)
- Letters read on TWiV 845
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkee
Send your questions for Dr. Griffin to [email protected]